Edward M Sellers

Summary

Publications

  1. ncbi request reprint Decreasing smoking behaviour and risk through CYP2A6 inhibition
    Edward M Sellers
    Department of Pharmacology, Psychiatry, Medicine University of Toronto, Ontario M5T 3A9, Toronto, Canada
    Drug Discov Today 8:487-93. 2003
  2. ncbi request reprint CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking
    Viba Malaiyandi
    Department of Pharmacology, Center for Addiction and Mental Health, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8
    Cancer Epidemiol Biomarkers Prev 15:1812-9. 2006
  3. pmc New CYP2A6 gene deletion and conversion variants in a population of Black African descent
    Jill C Mwenifumbo
    Department of Pharmacology, Room 4326 Medical Sciences Building, 1 King s College Circle, CAMH and University of Toronto, Toronto, ON M5S 1A8, Canada
    Pharmacogenomics 11:189-98. 2010
  4. pmc A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo
    Nael Al Koudsi
    Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
    Pharmacogenomics J 9:274-82. 2009
  5. ncbi request reprint Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method
    Jill C Mwenifumbo
    University of Toronto, Toronto, Canada
    Pharmacogenet Genomics 15:189-92. 2005
  6. doi request reprint Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent
    Jill C Mwenifumbo
    Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Hum Mutat 29:679-88. 2008
  7. ncbi request reprint Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19
    Wenjiang Zhang
    Center for Addiction and Mental Health, University of Toronto, Toronto, Canada
    Drug Metab Dispos 30:663-9. 2002
  8. ncbi request reprint Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics
    Nael Al Koudsi
    Centre for Addiction and Mental Health, and Department of Pharmacology, University of Toronto, Toronto, ON, Canada
    Eur J Clin Pharmacol 62:481-4. 2006
  9. ncbi request reprint Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians
    Kerri A Schoedel
    Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Pharmacogenetics 14:615-26. 2004
  10. ncbi request reprint Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro
    Yamini Ramamoorthy
    Department of Pharmacology, University of Toronto, Ont, Canada
    Biochem Pharmacol 63:2111-9. 2002

Collaborators

Detail Information

Publications42

  1. ncbi request reprint Decreasing smoking behaviour and risk through CYP2A6 inhibition
    Edward M Sellers
    Department of Pharmacology, Psychiatry, Medicine University of Toronto, Ontario M5T 3A9, Toronto, Canada
    Drug Discov Today 8:487-93. 2003
    ..Further, we discuss a range of models for proof-of-concept studies for new treatments to alleviate tobacco dependence..
  2. ncbi request reprint CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking
    Viba Malaiyandi
    Department of Pharmacology, Center for Addiction and Mental Health, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8
    Cancer Epidemiol Biomarkers Prev 15:1812-9. 2006
    ....
  3. pmc New CYP2A6 gene deletion and conversion variants in a population of Black African descent
    Jill C Mwenifumbo
    Department of Pharmacology, Room 4326 Medical Sciences Building, 1 King s College Circle, CAMH and University of Toronto, Toronto, ON M5S 1A8, Canada
    Pharmacogenomics 11:189-98. 2010
    ..Cytochrome P450 2A6 (CYP2A6) is a human enzyme best known for metabolizing nicotine and nitrosamine precarcinogens. Our aim was to discover and characterize new CYP2A6 alleles in a population of Black African descent...
  4. pmc A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo
    Nael Al Koudsi
    Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
    Pharmacogenomics J 9:274-82. 2009
    ..In conclusion, we identified three novel CYP2A6 alleles (CYP2A6(*)35, (*)36 and (*)37); the higher allele frequency variant CYP2A6(*)35 was associated with lower CYP2A6 activity...
  5. ncbi request reprint Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method
    Jill C Mwenifumbo
    University of Toronto, Toronto, Canada
    Pharmacogenet Genomics 15:189-92. 2005
    ..Our new method demonstrated higher frequencies of CYP2A6*7 and CYP2A6*10, and a lower frequency of CYP2A6*8 in Asian populations, but no significant change of allele frequencies in Caucasian or African-Canadian populations...
  6. doi request reprint Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent
    Jill C Mwenifumbo
    Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Hum Mutat 29:679-88. 2008
    ..These findings are important for increasing the accuracy of association studies between CYP2A6 genotype and behavioral, disease, or pharmacological phenotypes...
  7. ncbi request reprint Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19
    Wenjiang Zhang
    Center for Addiction and Mental Health, University of Toronto, Toronto, Canada
    Drug Metab Dispos 30:663-9. 2002
    ..The apparent selectivity of this pathway for CYP2C19 suggests 18-MC as a potentially useful probe of CYP2C19 activity in vitro and in vivo...
  8. ncbi request reprint Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics
    Nael Al Koudsi
    Centre for Addiction and Mental Health, and Department of Pharmacology, University of Toronto, Toronto, ON, Canada
    Eur J Clin Pharmacol 62:481-4. 2006
    ..The impact of CYP2A6*21 (K476R) on in vivo nicotine metabolism and disposition was investigated...
  9. ncbi request reprint Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians
    Kerri A Schoedel
    Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Pharmacogenetics 14:615-26. 2004
    ..Slow inactivators also smoked fewer cigarettes per day and had an earlier age of first smoking (only dependent smokers)...
  10. ncbi request reprint Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro
    Yamini Ramamoorthy
    Department of Pharmacology, University of Toronto, Ont, Canada
    Biochem Pharmacol 63:2111-9. 2002
    ..These individuals, and those taking CYP2D6 inhibitors, may demonstrate altered acute and/or long-term MDMA-related toxicity...
  11. ncbi request reprint Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro
    Wenjiang Zhang
    Department of Pharmacology, University of Toronto, Ontario, Canada
    Drug Metab Dispos 31:768-72. 2003
    ....
  12. ncbi request reprint CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence
    Lisa A Howard
    Department of Pharmacology, University of Toronto, Ontario, Canada
    Pharmacogenetics 13:321-8. 2003
    ....
  13. doi request reprint Effect of metabolic blockade on the psychoactive effects of dextromethorphan
    Laurie A Zawertailo
    Centre for Addiction and Mental Health, Nicotine Dependence Clinic, Toronto, Ontario, Canada
    Hum Psychopharmacol 25:71-9. 2010
    ..This study examined whether pharmacological inhibition of CYP2D6 activity with quinidine would mimic the genetic mutation and thus also alter the psychoactive effects of DM...
  14. ncbi request reprint The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo
    Edward M Sellers
    Department of Pharmacology, and Centre for Research in Women s Health, University of Toronto, Ontario, Canada
    Nicotine Tob Res 5:891-9. 2003
    ..CYP2A6 inhibition may have potential as an exposure reduction or cessation strategy in tobacco dependence...
  15. doi request reprint Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users
    Kerri A Schoedel
    INC Research, Toronto, Ontario, Canada
    J Clin Psychopharmacol 32:492-502. 2012
    ..Because of central nervous system effects, the study was performed to assess the abuse potential and cognitive effects of taranabant in recreational polydrug users compared with phentermine, dronabinol, and placebo...
  16. doi request reprint Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone
    Megan J Shram
    Clinical Pharmacology Group, Kendle Early Stage, Toronto, Ontario, Canada
    J Clin Psychopharmacol 30:25-33. 2010
    ..Delayed onset of good drug effects and prominent bad drug effects of hydromorphone ER suggest that, when administered intact, this formulation may have lower abuse potential than hydromorphone IR...
  17. ncbi request reprint Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users
    Kerri A Schoedel
    Kendle Early Stage, Toronto, Ontario, Canada
    J Opioid Manag 7:179-92. 2011
    ..To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)...
  18. ncbi request reprint Designer drugs that are potent inhibitors of CYP2D6
    David Pritzker
    Department of Pharmacology, University of Toronto, Canada
    J Clin Psychopharmacol 22:330-2. 2002
    ..quot; No CYP2D6-mediated metabolites were detected for either compound. Concurrent oral use of CYP2D6 substrates with MPPP and PEPAP may represent a kinetic drug interaction risk, but this risk must be confirmed clinically...
  19. ncbi request reprint Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration
    Kerri A Schoedel
    Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Mol Pharmacol 63:96-104. 2003
    ..Consistent with the slower nicotine metabolism observed in smokers, nicotine may decrease its own metabolism in primates by decreasing the expression of the primary nicotine-metabolizing enzyme CYP2A6...
  20. doi request reprint A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use
    Kerri Alexandra Schoedel
    Kendle Early Stage Toronto, Toronto, Ontario, Canada
    Hum Psychopharmacol 26:224-36. 2011
    ..This study aimed to evaluate the abuse potential and cognitive effects of nabiximols (Sativex, GW Pharma Ltd. Salisbury, UK), an oromucosal spray primarily containing delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD)...
  21. doi request reprint Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers
    Kerri A Schoedel
    INC Research Toronto, Toronto, Canada
    Clin Drug Investig 32:157-69. 2012
    ....
  22. doi request reprint Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria
    Megan J Shram
    INC Research, Toronto, Ontario, Canada
    Clin Ther 34:1170-81. 2012
    ..In the case of complex modified-release formulations, these criteria may not address pharmacokinetic differences with potential therapeutic and tolerability implications...
  23. ncbi request reprint Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use
    William Chu
    Department of Radiation Oncology, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    Carcinogenesis 28:2139-42. 2007
    ..004). These findings suggest that a subgroup of breast cancer patients who carry the CYP3A4*1B allele and take tamoxifen may be at increased risk of developing endometrial cancer...
  24. doi request reprint Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers
    Denise Milovan
    Kendle Early Stage, Toronto, ON, Canada
    Epilepsy Behav 18:366-73. 2010
    ..Eslicarbazepine acetate and oxcarbazepine had similar overall cognitive profiles and did not cause clinically relevant cognitive impairment. The incidence of adverse events was lower with eslicarbazepine acetate than with oxcarbazepine...
  25. pmc Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent
    Jill C Mwenifumbo
    The Centre for Addiction and Mental Health and Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Nicotine Tob Res 10:1319-25. 2008
    ..001). Overall, lower education levels, divorce, and alcohol and marijuana use were significantly associated with increased likelihood of smoking among this population...
  26. ncbi request reprint Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults
    Yanhua Zhang
    Department of Pharmacology, University of Toronto, ON, Canada
    J Clin Pharmacol 46:345-52. 2006
    ..2%, with a median 30.0%. No sex or menstrual cycle differences in CYP3A activity as measured by the probe drug omeprazole were seen. Higher CYP3A activity in women may be associated with higher endogenous progesterone concentrations...
  27. ncbi request reprint Treatment of codeine dependence with inhibitors of cytochrome P450 2D6
    Leona C Fernandes
    Sunnybrook and Women s College Health Sciences Centre, Women s College Campus, Toronto, Ontario, Canada
    J Clin Psychopharmacol 22:326-9. 2002
    ..In this small sample, CYP2D6 inhibitors did not appear to have a useful role in the treatment of codeine dependence...
  28. ncbi request reprint Relative abuse potential of opioid formulations in Canada: a structured field study
    Edward M Sellers
    Ventana Clinical Research Corporation, Toronto, Ontario, Canada
    J Opioid Manag 2:219-27. 2006
    ..This field study characterizes the relative susceptibility and attractiveness of a new analgesic patch, with fentanyl embedded in a matrix material, compared to other opioid dose formulations...
  29. ncbi request reprint Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism
    Alina L Micu
    Department of Pharmacology, University of Toronto, Canada
    J Pharmacol Exp Ther 306:941-7. 2003
    ..g., smokers, patients with Alzheimer's disease, ulcerative colitis or Parkinson's disease)...
  30. ncbi request reprint The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence
    Lisa A Howard
    Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada, M5S 1A8
    Pharmacogenomics 3:185-99. 2002
    ....
  31. ncbi request reprint Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior
    Rachel F Tyndale
    Center for Addictions and Mental Health, Toronto, Canada
    Ther Drug Monit 24:163-71. 2002
    ....
  32. ncbi request reprint Inhibition of cytochromes P450 by antifungal imidazole derivatives
    Wenjiang Zhang
    Department of Pharmacology, University of Toronto, Ontario, Canada
    Drug Metab Dispos 30:314-8. 2002
    ..4 microM), and CYP3A4 (clotrimazole K(i), 0.02 microM; miconazole K(i), 0.03 microM; tioconazole K(i), 0.02 microM). Therefore, this class of compounds is likely to result in significant drug-drug interactions in vivo...
  33. ncbi request reprint Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone
    Kerri A Schoedel
    Kendle Early Stage, Toronto, ON, Canada
    Pain Physician 13:561-73. 2010
    ..Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects...
  34. ncbi request reprint Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital
    Laurie A Zawertailo
    Psychopharmacology and Dependence Research Unit, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 23:269-80. 2003
    ....
  35. doi request reprint The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential
    Robert S Mansbach
    Kendle Early Stage Toronto, 720 King Street West, Toronto, Ontario M5V 2T3, Canada
    Drug Alcohol Depend 112:173-7. 2010
    ..Such an effort would aid in implementing the evolving efforts of health authorities to guide drug developers in the collection and presentation of data needed for the regulation of drugs with the potential for abuse and dependence...
  36. ncbi request reprint Research design strategies to evaluate the impact of formulations on abuse liability
    Shelley McColl
    Ventana Clinical Research Corporation, Toronto, Canada
    Drug Alcohol Depend 83:S52-62. 2006
    ..Post-marketing epidemiological data demonstrating the lack of abuse will carry the most weight from a public health and physician perspective...
  37. ncbi request reprint EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study
    David Mamo
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Psychopharmacology (Berl) 175:382-8. 2004
    ..The data suggest that daily dosing of > or =3 mg EMD 281014 should be sufficient to provide sustained high levels of 5HT2-receptor occupancy in future clinical trials...
  38. ncbi request reprint CYP2A6 genetic variation and potential consequences
    Chun Xu
    Centre for Addiction and Mental Health, University of Toronto, Toronto M5S 1A8, Canada
    Adv Drug Deliv Rev 54:1245-56. 2002
    ....
  39. ncbi request reprint Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence
    Viba Malaiyandi
    Department of Pharmacology and Medicine, 1 King s College Circle, University of Toronto, Canada M5S 1A8
    Clin Pharmacol Ther 77:145-58. 2005
    ..Implications of these recent findings on current and novel treatment approaches for smoking cessation and tobacco-related lung cancer will also be discussed...
  40. ncbi request reprint Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking
    Jill C Mwenifumbo
    The Centre for Addiction and Mental Health and the Department of Pharmacology, University of Toronto, Canada M5S 1A8
    Drug Alcohol Depend 89:24-33. 2007
    ..005). These findings highlight the need for smoking status and gender to be considered when interpreting studies using nicotine...
  41. ncbi request reprint Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping
    Myong Jin Kim
    Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326 1394, USA
    J Clin Pharmacol 44:966-73. 2004
    ..5%, interquartile range = 14.8%-23.5%). Weight-based single doses of omeprazole for CYP2C19 phenotyping did not exhibit dose dependency. Therefore, a weight-based approach may improve the quantitation of omeprazole/metabolites...
  42. ncbi request reprint Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker
    Myong Jin Kim
    Clinical Pharmacology Research Center, Department of Medicine, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326 1394, USA
    Clin Pharmacol Ther 72:192-9. 2002
    ..However, the effect of variations in endogenous sex steroid concentrations throughout the menstrual cycle has not been investigated...